Quantcast
Home > Quotes > EYEG

Eyegate Pharmaceuticals, Inc. Common Stock (EYEG) Quote & Summary Data

EYEG 
$0.53
*  
0.0298
5.96%
Get EYEG Alerts
*Delayed - data as of Dec. 14, 2018  -  Find a broker to begin trading EYEG now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
4.25
Today's High / Low
$ 0.53 / $ 0.5008
Share Volume
254,002
50 Day Avg. Daily Volume
1,494,887
Previous Close
$ 0.5002
52 Week High / Low
$ 1.34 / $ 0.275
Market Cap
23,025,255
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-1

Intraday Chart

Shares Traded

Share Volume:
254,002
50 Day Avg. Daily Volume:
1,494,887

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.42

Trading Range

The current last sale of $0.53 is 92.73% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.53 $ 1.34
 Low: $ 0.5008 $ 0.275

Company Description (as filed with the SEC)

We are a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. We accomplish this by leveraging our two proprietary platform technologies, crosslinked thiolated carboxymethyl hyaluronic acid ("CMHA-S") and our iontophoresis drug delivery system. We are developing products using CMHA-S, a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing properties when applied to the ocular surface. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries. Our first CMHA-S-based product, the EyeGate Ocular Bandage Gel ("OBG"), has completed a pilot trial where we announced positive top-line data.  ... More ...  


Risk Grade

Where does EYEG fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.53
Open Date:
Dec. 14, 2018
Close Price:
$ 0.53
Close Date:
Dec. 14, 2018

Consensus Recommendation

Analyst Info